Aspirin reduces the risk of type 2 diabetes associated with COVID-19.

npj Metabolic Health and Disease Pub Date : 2025-06-18 DOI:10.1038/s44324-025-00072-3

Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco

{"title":"Aspirin reduces the risk of type 2 diabetes associated with COVID-19.","authors":"Valentina Trimarco, Raffaele Izzo, Daniela Pacella, Maria Virginia Manzi, Stanislovas S Jankauskas, Paola Gallo, Francesco Rozza, Giuseppe Giugliano, Alessandra Spinelli, Giovanni Esposito, Roberto Piccinocchi, Gaetano Piccinocchi, Carmine Morisco, Maria Lembo, Gaetano Santulli, Bruno Trimarco","doi":"10.1038/s44324-025-00072-3","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.</p>","PeriodicalId":501710,"journal":{"name":"npj Metabolic Health and Disease","volume":"3 1","pages":"27"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177057/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Metabolic Health and Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s44324-025-00072-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

This study aimed to determine whether daily low-dose aspirin reduces the risk of type 2 diabetes (T2D) associated with COVID-19. A longitudinal cohort of 200,000 adults followed from 2018 to 2022 was analyzed, comparing T2D incidence between aspirin users and non-users. Propensity score matching was used to balance the groups. The incidence of T2D was substantially lower in the aspirin group, with Cox regression showing a 52% risk reduction. Kaplan-Meier analysis confirmed a significant divergence in cumulative T2D risk after two years. This protective effect was observed both before and during the COVID-19 pandemic, with a stronger association during the pandemic period. These findings indicate that daily low-dose aspirin significantly reduces the risk of COVID-19-associated new-onset T2D, highlighting the role of inflammation in the pathogenesis of T2D triggered or unmasked by COVID-19.

查看原文本刊更多论文

阿司匹林可降低与COVID-19相关的2型糖尿病的风险。

本研究旨在确定每日低剂量阿司匹林是否能降低与COVID-19相关的2型糖尿病（T2D）的风险。对2018年至2022年随访的20万成年人的纵向队列进行了分析，比较了阿司匹林使用者和非使用者之间的T2D发病率。倾向得分匹配用于平衡组。阿司匹林组T2D的发生率显著降低，Cox回归显示风险降低52%。Kaplan-Meier分析证实了两年后累积T2D风险的显著差异。在COVID-19大流行之前和期间都观察到这种保护作用，在大流行期间，这种关联更强。这些研究结果表明，每日低剂量阿司匹林可显著降低与COVID-19相关的新发T2D的风险，突出了炎症在COVID-19引发或揭露的T2D发病机制中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

npj Metabolic Health and Disease

自引率

0.00%

发文量